21.58  -0.75 (-3.36%)		06-04 12:02
Open: 22.26 High: 23.54 Volume: 609		Pre. Close: 22.33 Low: 21.58 Market Cap: 34(M)

Short term
Mid term
Targets	6-month :	29.65	1-year :	34.63
Resists	First :	25.38	Second :	29.65
Pivot price	0
Supports	First :	24.16	Second :	23.4
MAs	MA(5) :	0	MA(20) :	0
	MA(100) :	0	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	0	D(3) :	0
RSI	RSI(14): 0
52-week	High :	25.38	Low :	23.4

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ GLTO ] has closed Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Galecto, Inc. is a clinical-stage biotechnology company focused on creating new therapeutic agents for a range of illnesses, including fibrotic conditions, cancer, and inflammation. Its most advanced investigational drug, GB2064, is currently undergoing Phase IIa clinical studies to treat myelofibrosis. The company is also developing GB0139, an inhalable compound that targets galectin-3, which is in Phase IIb trials for severe fibrotic lung disorders, such as idiopathic pulmonary fibrosis (IPF)—a serious and progressively worsening lung disease. Additionally, Galecto is advancing GB1211, a selective oral galectin-3 inhibitor, with ongoing Phase IIa trials for cancer and Phase Ib/IIa trials for fibrosis. Founded in 2011, Galecto, Inc. is headquartered in Boston, Massachusetts.

Mon, 09 Mar 2026
Galecto (GLTO) Rebrands to Damora Therapeutics, Plans Nasdaq Lis - GuruFocus

Sun, 15 Feb 2026
Galecto (GLTO) Is Up 15.3% After $316 Million Equity Raise And New Shelf Registration - What's Changed - Yahoo Finance

Sun, 15 Feb 2026
Assessing Galecto (GLTO) Valuation After Sharp Short-Term Share Price Momentum - Yahoo Finance

Thu, 12 Feb 2026
Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million - Bitget

Wed, 11 Feb 2026
Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - The Manila Times

Tue, 10 Feb 2026
Galecto announces CEO transition, share authorization increase, and shareholder approvals - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.